Scientist Home Future Health Ltd. Files S-1/A Amendment

TL;DR

Scientist Home Future Health Ltd. filed an S-1/A. Looks like they're still working on their registration.

AI Summary

Scientist Home Future Health Ltd. filed an S-1/A amendment on January 16, 2025, for its registration statement. The company, incorporated in Nevada, operates in the perfumes, cosmetics & other toilet preparations industry. Its principal executive offices are located in Kwun Tong, Hong Kong.

Why It Matters

This filing indicates ongoing regulatory activity for Scientist Home Future Health Ltd. as it progresses with its securities registration, potentially paving the way for future public offerings or compliance updates.

Risk Assessment

Risk Level: low — This is a routine S-1/A filing amendment, not indicating immediate financial distress or significant new risks.

Key Numbers

• 333-283430 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 25534431 — Film Number (Internal SEC processing number for the filing.)

Key Players & Entities

• Scientist Home Future Health Ltd (company) — Registrant
• January 16, 2025 (date) — Filing Date
• Nevada (jurisdiction) — State of Incorporation
• 2844 (sic_code) — Standard Industrial Classification
• Chan Siu Hung (person) — Chief Executive Officer
• +852 5702 3076 (phone_number) — Issuer's telephone number

FAQ

Key Financial Figures

• $0.0001 — ed 2,700,000 SHARES OF COMMON STOCK $0.0001 PAR VALUE PER SHARE Prior to this Off
• $1.50 — ompany will be sold at a fixed price of $1.50 per share for the duration of the Offer
• $4,050,000 — pany are sold, the Company will receive $4,050,000 in net proceeds. Assuming 2,025,000 sha
• $3,037,500 — pany are sold, the Company will receive $3,037,500 in net proceeds. Assuming 1,350,000 sha
• $2,025,000 — pany are sold, the Company will receive $2,025,000 in net proceeds. Assuming 675,000 share
• $1,012,500 — pany are sold, the Company will receive $1,012,500 in net proceeds. There is no minimum am
• $107,000 — tes the costs of this offering at about $107,000. All expenses incurred in this offering
• $10 — ubscription amount paid by Mr. Chan was $10. Mr. Chan serves as our Chief Executive
• $1,990 — ubscription amount paid by Mr. Chan was $1,990. On September 9, 2024, we sold 1,160,0
• $0.002 — n Kit, and Yuen Wai Ling, at a price of $0.002 per share of Common Stock. The total su
• $2,320 — scription amount paid by each party was $2,320. The total number of shares sold pursua
• $1.00 — n paid pursuant to this acquisition was $1.00. This transaction is classified as a re

Filing Documents

• scientist_s1a2.htm (S-1/A) — 788KB
• articles.htm (EX-3.1) — 1KB
• bylaws.htm (EX-3.2) — 54KB
• opinionletter.htm (EX-5.1) — 16KB
• ex101.htm (EX-10.1) — 108KB
• auditor_consent.htm (EX-23.1) — 3KB
• ex107.htm (EX-FILING FEES) — 5KB
• image_001.jpg (GRAPHIC) — 16KB
• image_002.jpg (GRAPHIC) — 43KB
• pg1.jpg (GRAPHIC) — 403KB
• pg2.jpg (GRAPHIC) — 396KB
• veincream.jpg (GRAPHIC) — 37KB
• calccream.jpg (GRAPHIC) — 43KB
• spermaceti.jpg (GRAPHIC) — 46KB
• leftimage.jpg (GRAPHIC) — 18KB
• rightpic.jpg (GRAPHIC) — 79KB
• gelleft.jpg (GRAPHIC) — 45KB
• gelright.jpg (GRAPHIC) — 270KB
• proteinleft.jpg (GRAPHIC) — 63KB
• proteinright.jpg (GRAPHIC) — 219KB
• filename22.htm (CORRESP) — 57KB
• 0001599916-25-000004.txt ( ) — 3343KB

PROSPECTUS

PART I PROSPECTUS PAGE PROSPECTUS SUMMARY 1 RISK FACTORS 4 SUMMARY OF OUR FINANCIAL INFORMATION 11 MANAGEMENT’S DISCUSSION AND ANALYSIS 13 INDUSTRY OVERVIEW 14 FORWARD-LOOKING 15 DESCRIPTION OF BUSINESS 15

USE OF PROCEEDS

USE OF PROCEEDS 16 DETERMINATION OF OFFERING PRICE 16

DILUTION

DILUTION 18 PLAN OF DISTRIBUTION 19 DESCRIPTION OF SECURITIES 20 INTERESTS OF NAMED EXPERTS AND COUNSEL 21 REPORTS TO SECURITIES HOLDERS 21 DESCRIPTION OF FACILITIES 21 LEGAL PROCEEDINGS 22 PATENTS AND TRADEMARKS 22 DIRECTORS AND EXECUTIVE OFFICERS 22 EXECUTIVE COMPENSATION 23 SECURITY 25 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 25 PRINCIPAL ACCOUNTING FEES AND SERVICES 25 MATERIAL CHANGES 25 FINANCIAL F1-F17

INFORMATION

PART II. INFORMATION NOT REQUIRED IN PROSPECTUS OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION 26 INDEMNIFICATION OF OFFICERS AND DIRECTORS 26 RECENT SALES OF UNREGISTERED SECURITIES 27 EXHIBITS TO THE REGISTRATION STATEMENT 27 UNDERTAKINGS 28

SIGNATURES

SIGNATURES 29 You should rely only on the information contained in this prospectus or contained in any free writing prospectus filed with the Securities and Exchange Commission. We have not authorized anyone to provide you with additional information or information different from that contained in this prospectus filed with the Securities and Exchange Commission. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We are offering to sell, and seeking offers to buy, our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. Through November 30, 2025 all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers' obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. Table of Contents PROSPECTUS SUMMARY In this Prospectus, “Scientist Home Future Health Limited,” “the Issuer,” the “Company,” “we,” “us,” and “our,” refer to Scientist Home Future Health Limited, unless the context otherwise requires. Unless otherwise indicated, the term ''fiscal year'' refers to our fiscal year ending December 31 th . Unless otherwise indicated, the term ''common stock'' refers to shares of the Company's common stock. This Prospectus, and any supplement to this Prospectus include “forward-looking statements”. To the extent that the information presented in this Prospectus discusses financial projections, information

View Full Filing

View this S-1/A filing on SEC EDGAR